129.81 USD
+0.17 (+0.13%)
129.81 USD
0 (0%)
Overall ILMN gets a fundamental rating of 6 out of 10. We evaluated ILMN against 58 industry peers in the Life Sciences Tools & Services industry. ILMN scores excellent on profitability, but there are some minor concerns on its financial health. ILMN is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make ILMN suitable for value investing!
1. Profitability
1.1 Basic Checks
In the past year ILMN was profitable.
ILMN had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ILMN reported negative net income in multiple years.
ILMN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
ILMN has a better Return On Assets (11.38%) than 91.38% of its industry peers.
With an excellent Return On Equity value of 29.53%, ILMN belongs to the best of the industry, outperforming 96.55% of the companies in the same industry.
ILMN's Return On Invested Capital of 16.40% is amongst the best of the industry. ILMN outperforms 91.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 16.39%, ILMN belongs to the best of the industry, outperforming 89.66% of the companies in the same industry.
ILMN has a Operating Margin of 20.41%. This is amongst the best in the industry. ILMN outperforms 86.21% of its industry peers.
In the last couple of years the Operating Margin of ILMN has declined.
ILMN has a Gross Margin of 66.74%. This is amongst the best in the industry. ILMN outperforms 87.93% of its industry peers.
ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
ILMN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
ILMN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ILMN has more shares outstanding
The debt/assets ratio for ILMN is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.31 indicates that ILMN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.31, ILMN is in the better half of the industry, outperforming 72.41% of the companies in the same industry.
The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.99, ILMN belongs to the best of the industry, outperforming 87.93% of the companies in the same industry.
ILMN has a Debt/Equity ratio of 0.42. This is a healthy value indicating a solid balance between debt and equity.
ILMN has a Debt to Equity ratio of 0.42. This is comparable to the rest of the industry: ILMN outperforms 41.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.31 |
ROIC/WACC1.65
WACC9.94%
2.3 Liquidity
ILMN has a Current Ratio of 1.43. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
ILMN has a worse Current ratio (1.43) than 79.31% of its industry peers.
A Quick Ratio of 1.12 indicates that ILMN should not have too much problems paying its short term obligations.
ILMN has a worse Quick ratio (1.12) than 70.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
ILMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 152.02%, which is quite impressive.
The earnings per share for ILMN have been decreasing by -17.93% on average. This is quite bad
Looking at the last year, ILMN shows a decrease in Revenue. The Revenue has decreased by -2.32% in the last year.
The Revenue has been growing slightly by 4.29% on average over the past years.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
ILMN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.99% yearly.
ILMN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.93% yearly.
EPS Next Y93.48%
EPS Next 2Y43.68%
EPS Next 3Y33.01%
EPS Next 5Y24.99%
Revenue Next Year-1.07%
Revenue Next 2Y0.57%
Revenue Next 3Y2.22%
Revenue Next 5Y3.93%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 29.77, ILMN can be considered very expensive at the moment.
ILMN's Price/Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 72.41% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, ILMN is valued at the same level.
The Price/Forward Earnings ratio is 25.67, which means the current valuation is very expensive for ILMN.
Based on the Price/Forward Earnings ratio, ILMN is valued a bit cheaper than 77.59% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ILMN to the average of the S&P500 Index (36.12), we can say ILMN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.77 | ||
| Fwd PE | 25.67 |
4.2 Price Multiples
ILMN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ILMN is cheaper than 82.76% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ILMN is valued cheaply inside the industry as 87.93% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.95 | ||
| EV/EBITDA | 17.77 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ILMN may justify a higher PE ratio.
ILMN's earnings are expected to grow with 33.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y43.68%
EPS Next 3Y33.01%
5. Dividend
5.1 Amount
No dividends for ILMN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
129.81
+0.17 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.96%
Inst Owner Change1.55%
Ins Owners0.18%
Ins Owner Change-0.36%
Market Cap19.95B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts72.86
Price Target120.47 (-7.2%)
Short Float %4.39%
Short Ratio3.77
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)5.82%
PT rev (3m)5.17%
EPS NQ rev (1m)4.11%
EPS NQ rev (3m)2.99%
EPS NY rev (1m)3.19%
EPS NY rev (3m)2.83%
Revenue NQ rev (1m)0.9%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0.37%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 29.77 | ||
| Fwd PE | 25.67 | ||
| P/S | 4.65 | ||
| P/FCF | 19.95 | ||
| P/OCF | 17.78 | ||
| P/B | 8.38 | ||
| P/tB | 19.13 | ||
| EV/EBITDA | 17.77 |
EPS(TTM)4.36
EY3.36%
EPS(NY)5.06
Fwd EY3.9%
FCF(TTM)6.51
FCFY5.01%
OCF(TTM)7.3
OCFY5.62%
SpS27.9
BVpS15.49
TBVpS6.79
PEG (NY)0.32
PEG (5Y)N/A
Graham Number38.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.31 |
F-Score7
WACC9.94%
ROIC/WACC1.65
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y93.48%
EPS Next 2Y43.68%
EPS Next 3Y33.01%
EPS Next 5Y24.99%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-1.07%
Revenue Next 2Y0.57%
Revenue Next 3Y2.22%
Revenue Next 5Y3.93%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year30.85%
EBIT Next 3Y15.15%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 6 / 10 to ILMN.
What is the valuation status for ILMN stock?
ChartMill assigns a valuation rating of 7 / 10 to ILLUMINA INC (ILMN). This can be considered as Undervalued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
How financially healthy is ILLUMINA INC?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
Can you provide the expected EPS growth for ILMN stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 93.48% in the next year.